These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 10415735)

  • 1. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials.
    Shalinsky DR; Brekken J; Zou H; McDermott CD; Forsyth P; Edwards D; Margosiak S; Bender S; Truitt G; Wood A; Varki NM; Appelt K
    Ann N Y Acad Sci; 1999 Jun; 878():236-70. PubMed ID: 10415735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
    Shalinsky DR; Brekken J; Zou H; Bloom LA; McDermott CD; Zook S; Varki NM; Appelt K
    Clin Cancer Res; 1999 Jul; 5(7):1905-17. PubMed ID: 10430098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340.
    Price A; Shi Q; Morris D; Wilcox ME; Brasher PM; Rewcastle NB; Shalinsky D; Zou H; Appelt K; Johnston RN; Yong VW; Edwards D; Forsyth P
    Clin Cancer Res; 1999 Apr; 5(4):845-54. PubMed ID: 10213221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations.
    Shalinsky DR; Brekken J; Zou H; Kolis S; Wood A; Webber S; Appelt K
    Invest New Drugs; 1998-1999; 16(4):303-13. PubMed ID: 10426662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models.
    Lozonschi L; Sunamura M; Kobari M; Egawa S; Ding L; Matsuno S
    Cancer Res; 1999 Mar; 59(6):1252-8. PubMed ID: 10096556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early combined treatment with carboplatin and the MMP inhibitor, prinomastat, prolongs survival and reduces systemic metastasis in an aggressive orthotopic lung cancer model.
    Liu J; Tsao MS; Pagura M; Shalinsky DR; Khoka R; Fata J; Johnston MR
    Lung Cancer; 2003 Dec; 42(3):335-44. PubMed ID: 14644522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor.
    Maekawa R; Maki H; Yoshida H; Hojo K; Tanaka H; Wada T; Uchida N; Takeda Y; Kasai H; Okamoto H; Tsuzuki H; Kambayashi Y; Watanabe F; Kawada K; Toda K; Ohtani M; Sugita K; Yoshioka T
    Cancer Res; 1999 Mar; 59(6):1231-5. PubMed ID: 10096553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.
    Tortora G; Caputo R; Damiano V; Caputo R; Troiani T; Veneziani BM; De Placido S; Bianco AR; Zangemeister-Wittke U; Ciardiello F
    Clin Cancer Res; 2003 Feb; 9(2):866-71. PubMed ID: 12576461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.
    Prontera C; Mariani B; Rossi C; Poggi A; Rotilio D
    Int J Cancer; 1999 May; 81(5):761-6. PubMed ID: 10328230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases.
    Scatena R
    Expert Opin Investig Drugs; 2000 Sep; 9(9):2159-65. PubMed ID: 11060800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity.
    Tortora G; Caputo R; Damiano V; Fontanini G; Melisi D; Veneziani BM; Zunino F; Bianco AR; Ciardiello F
    Clin Cancer Res; 2001 Dec; 7(12):4156-63. PubMed ID: 11751516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic and genetic manipulation of MMP-2 and -9 affects retinal neovascularization in rodent models of OIR.
    Barnett JM; McCollum GW; Fowler JA; Duan JJ; Kay JD; Liu RQ; Bingaman DP; Penn JS
    Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):907-15. PubMed ID: 17251494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291.
    Naglich JG; Jure-Kunkel M; Gupta E; Fargnoli J; Henderson AJ; Lewin AC; Talbott R; Baxter A; Bird J; Savopoulos R; Wills R; Kramer RA; Trail PA
    Cancer Res; 2001 Dec; 61(23):8480-5. PubMed ID: 11731431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
    Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
    Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice.
    Sledge GW; Qulali M; Goulet R; Bone EA; Fife R
    J Natl Cancer Inst; 1995 Oct; 87(20):1546-50. PubMed ID: 7563189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
    Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
    Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.
    Walsh C; Tanjoni I; Uryu S; Tomar A; Nam JO; Luo H; Phillips A; Patel N; Kwok C; McMahon G; Stupack DG; Schlaepfer DD
    Cancer Biol Ther; 2010 May; 9(10):778-90. PubMed ID: 20234193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis.
    Deryugina EI; Soroceanu L; Strongin AY
    Cancer Res; 2002 Jan; 62(2):580-8. PubMed ID: 11809713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts.
    Teicher BA; Menon K; Alvarez E; Shih C; Faul MM
    Invest New Drugs; 2002 Aug; 20(3):241-51. PubMed ID: 12201487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.